Medical News Today |
Severe asthma: Eczema drug succeeds where others fail
Medical News Today Two new studies show that a common eczema drug reduces asthma symptoms and improves lung function in people who have severe asthma. Eczema drug alleviates asthma symptoms and improves lung function Costly eczema injection also helps relieve severe asthma: Study Eczema drug reduces symptoms of severe asthma |
Tag Archives: Drug
A single drug may control skin cancer treatment costs
A $ 78 single course of topical fluorouracil for keratinocyte carcinoma and actinic keratosis lesions, could lead to a savings in the hundreds of dollars in follow-up costs.
Dermatology Times – Dermatology
FDA approves a new, more powerful psoriasis drug
“As we move toward finding a cure for psoriasis, what we are looking for are high performance drugs that provide durable response in between treatments and that lend themselves to patient compliance,” says Dr. George Martin.
Dermatology Times – Dermatology
How RA, Cancer, Hep C Drug Costs Will Change Over Next Five Years
Sanofi and Regeneron encounter more payer resistance over new eczema drug — this time, in the UK – STAT
STAT |
Sanofi and Regeneron encounter more payer resistance over new eczema drug — this time, in the UK
STAT nce again, Sanofi (SNY 1) and Regeneron Pharmaceuticals (REGN 2) are running into roadblocks trying to win over payers with their new drug for severe eczema. The latest frustration is occurring in the U.K., where a government watchdog decided the drug … Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Opinion: Time to Manage ‘Clinically Superfluous’ Drug Products to Control Costs
PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
Modern medicine – dermatology
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe – Investor’s Business Daily
Investor’s Business Daily |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
Investor’s Business Daily Technology. Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe. ALLISON GATLIN; 2/07/2018. Facebook · LinkedIn · Twitter · Print · Share. Reprints. Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Dupixent is off to a strong start in the U … |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe – Investor’s Business Daily
Investor’s Business Daily |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
Investor’s Business Daily Technology. Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe. ALLISON GATLIN; 2/07/2018. Facebook · LinkedIn · Twitter · Print · Share · Reprints. Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Dupixent is off to a strong start in the U … |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe – Investor’s Business Daily
Investor’s Business Daily |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
Investor’s Business Daily Technology. Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe. ALLISON GATLIN; 2/07/2018. Facebook · LinkedIn · Twitter · Print · Share. Reprints. Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Dupixent is off to a strong start in the U … |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe – Investor’s Business Daily
Investor’s Business Daily |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
Investor’s Business Daily Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Dupixent is off to a strong start in the U.S., but revenue from the eczema drug lagged in Europe, an analyst said Wednesday after Sanofi's fourth-quarter report. X Dupixent generated 118 million euros … |